![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/GLENMARK.png)
Share the post "Glenmark Pharmaceuticals ‘s Q3 2024-25 Latest News: Revenue Grows by 35.14% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 35.14 % in the past year, decrease in net sales/revenue by -1.35 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 199.41 %. Marginal decrease of -21.03% in other income during this quarter. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Glenmark Pharmaceuticals Limited. Profit dropped by -205.2 % Year to Year, Glenmark Pharmaceuticals Limited’s profitability dropped by -1.82 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS declined by -199.04 % Year to Year. EPS decreased by -1.75 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 2506.701 Cr | Rs. 3433.796 Cr | Rs. 3387.552 Cr | -1.35 % | + 35.14 % |
| Expenses | Rs. 2715.35 Cr | Rs. 2831.88 Cr | Rs. 2787.33 Cr | -1.57 % | + 2.65 % |
| Operating Profit | Rs. -208.65 Cr | Rs. 601.92 Cr | Rs. 600.22 Cr | -0.28 % | + 387.67 % |
| OPM % | -8.32 % | 17.53 % | 17.72 % | + 0.19 % | + 26.04 % |
| Other Income | Rs. -31.314 Cr | Rs. 39.417 Cr | Rs. 31.128 Cr | -21.03 % | + 199.41 % |
| Interest | Rs. 134.34 Cr | Rs. 48.48 Cr | Rs. 52.29 Cr | + 7.86 % | -61.08 % |
| Depreciation | Rs. 147.08 Cr | Rs. 120.28 Cr | Rs. 122.74 Cr | + 2.05 % | -16.55 % |
| Profit before tax | Rs. -521.38 Cr | Rs. 472.58 Cr | Rs. 456.32 Cr | -3.44 % | + 187.52 % |
| Tax % | -13.77 % | 24.99 % | 23.73 % | -1.26 % | + 37.5 % |
| Net Profit | Rs. -330.82 Cr | Rs. 354.49 Cr | Rs. 348.03 Cr | -1.82 % | + 205.2 % |
| EPS in Rs | Rs. -12.45 | Rs. 12.55 | Rs. 12.33 | -1.75 % | + 199.04 % |
Today, we’re looking at Glenmark Pharmaceuticals Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 35.14 %. However, it did see a marginal slip of -1.35 % from the previous quarter. Expenses decreased slightly by -1.57 % quarter-on-quarter, aligning with the annual rise of 2.65 %. Operating profit, while up 387.67 % compared to last year, faced a quarter-on-quarter dip of -0.28 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 26.04 %, but an expansion of 0.19 % sequentially. Other income fell by -21.03 % compared to the last quarter, despite an annual growth of 199.41 %. Interest expenses surged remarkably by 7.86 % from the previous quarter, yet the year-over-year decrease remains at a moderate -61.08 %. Depreciation costs climbed by 2.05 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -16.55 %. Profit before tax grew annually by 187.52 % but saw a reduction from the preceding quarter by -3.44 %.
Tax expenses as a percentage of profits increased slightly by 37.5 % compared to last year, with a more notable quarter-on-quarter decrease of -1.26 %. Net profit rose by 205.2 % year-on-year but witnessed a -1.82 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 199.04 % but a quarterly fall of -1.75 %. In summary, Glenmark Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 2506.701 Cr | Rs. 3433.796 Cr | Rs. 3387.552 Cr | -1.35 % | + 35.14 % |
| Expenses | Rs. 2715.35 Cr | Rs. 2831.88 Cr | Rs. 2787.33 Cr | -1.57 % | + 2.65 % |
| Operating Profit | Rs. -208.65 Cr | Rs. 601.92 Cr | Rs. 600.22 Cr | -0.28 % | + 387.67 % |
| Net Profit | Rs. -330.82 Cr | Rs. 354.49 Cr | Rs. 348.03 Cr | -1.82 % | + 205.2 % |
| EPS in Rs | Rs. -12.45 | Rs. 12.55 | Rs. 12.33 | -1.75 % | + 199.04 % |
In reviewing Glenmark Pharmaceuticals Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 35.14 % year-on-year growth, although there was a slight dip of -1.35 % from the previous quarter. Expenses rose by 2.65 % compared to the previous year, with a decrease of -1.57 % quarter-on-quarter. Operating Profit surged by 387.67 % annually, and saw a -0.28 % decrease from the last quarter.
Net Profit showed yearly increase of 205.2 %, and experienced a -1.82 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 199.04 % annually, however dipped by -1.75 % compared to the last quarter. In essence, while Glenmark Pharmaceuticals Limited exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/HMVL.png)
